The future of minimal residual disease detection is here
Powering therapeutic breakthroughs with next-level ctDNA sensitivity
Ultra-sensitive
Limit of detection as low as 1 ppm (LOD95), delivering 100–1,000× greater sensitivity than existing MRD approaches
Whole genome precision
Go beyond personalized panels with our whole genome baseline × whole genome monitoring, capturing rare variants in a complex tumor environment
Clinically validated
Leverage the power of a CAP/CLIA assay to accelerate the clinical and regulatory path for novel therapies
Value without compromise
Generate 5× to 100× more reads per sample, yielding more genomic data per assay than existing panel-based MRD assays – without sacrificing quality or budget. Scale your project with confidence for maximum impact
Submit a request
An exclusively whole genome approach delivering comprehensive insights, a simplified workflow, and ultra-precise monitoring.